These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 30655535

  • 1. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.
    Nat Commun; 2019 Jan 17; 10(1):278. PubMed ID: 30655535
    [Abstract] [Full Text] [Related]

  • 2. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
    Ci X, Hao J, Dong X, Xue H, Wu R, Choi SYC, Haegert AM, Collins CC, Liu X, Lin D, Wang Y.
    Cells; 2020 Jun 04; 9(6):. PubMed ID: 32512818
    [Abstract] [Full Text] [Related]

  • 3. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.
    Gigascience; 2018 Jun 01; 7(6):. PubMed ID: 29757368
    [Abstract] [Full Text] [Related]

  • 4. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.
    Cancer Discov; 2017 Jan 01; 7(1):54-71. PubMed ID: 27784708
    [Abstract] [Full Text] [Related]

  • 5. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.
    Rotinen M, You S, Yang J, Coetzee SG, Reis-Sobreiro M, Huang WC, Huang F, Pan X, Yáñez A, Hazelett DJ, Chu CY, Steadman K, Morrissey CM, Nelson PS, Corey E, Chung LWK, Freedland SJ, Di Vizio D, Garraway IP, Murali R, Knudsen BS, Freeman MR.
    Nat Med; 2018 Dec 01; 24(12):1887-1898. PubMed ID: 30478421
    [Abstract] [Full Text] [Related]

  • 6. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y, Rajabi H, Jin C, Hata T, Pitroda S, Long MD, Hagiwara M, Li W, Hu Q, Liu S, Yamashita N, Fushimi A, Kui L, Samur M, Yamamoto M, Zhang Y, Zhang N, Hong D, Maeda T, Kosaka T, Wong KK, Oya M, Kufe D.
    Nat Commun; 2020 Jan 17; 11(1):338. PubMed ID: 31953400
    [Abstract] [Full Text] [Related]

  • 7. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y, Xie N, Chen R, Lee AR, Lovnicki J, Morrison EA, Fazli L, Zhang Q, Musselman CA, Wang Y, Huang J, Gleave ME, Collins C, Dong X.
    Eur Urol; 2019 Aug 17; 76(2):157-166. PubMed ID: 30910347
    [Abstract] [Full Text] [Related]

  • 8. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
    Bae SY, Bergom HE, Day A, Greene JT, Sychev ZE, Larson G, Corey E, Plymate SR, Freedman TS, Hwang JH, Drake JM.
    Front Endocrinol (Lausanne); 2023 Aug 17; 14():1093332. PubMed ID: 37065756
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
    Hsu EC, Shen M, Aslan M, Liu S, Kumar M, Garcia-Marques F, Nguyen HM, Nolley R, Pitteri SJ, Corey E, Brooks JD, Stoyanova T.
    Sci Rep; 2021 Jun 25; 11(1):13305. PubMed ID: 34172788
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
    Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, Witte ON.
    Cancer Cell; 2016 Apr 11; 29(4):536-547. PubMed ID: 27050099
    [Abstract] [Full Text] [Related]

  • 13. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
    Lee AR, Gan Y, Tang Y, Dong X.
    EBioMedicine; 2018 Sep 11; 35():167-177. PubMed ID: 30100395
    [Abstract] [Full Text] [Related]

  • 14. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y, Donmez N, Sahinalp C, Xie N, Wang Y, Xue H, Mo F, Beltran H, Gleave M, Wang Y, Collins C, Dong X.
    Eur Urol; 2017 Jan 11; 71(1):68-78. PubMed ID: 27180064
    [Abstract] [Full Text] [Related]

  • 15. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
    Tiwari R, Manzar N, Bhatia V, Yadav A, Nengroo MA, Datta D, Carskadon S, Gupta N, Sigouros M, Khani F, Poutanen M, Zoubeidi A, Beltran H, Palanisamy N, Ateeq B.
    Nat Commun; 2020 Jan 20; 11(1):384. PubMed ID: 31959826
    [Abstract] [Full Text] [Related]

  • 16. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Wang J, Li J, Yin L, Pu T, Wei J, Karthikeyan V, Lin TP, Gao AC, Wu BJ.
    Oncogene; 2022 Sep 20; 41(37):4307-4317. PubMed ID: 35986103
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
    Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML.
    Nat Commun; 2021 Mar 30; 12(1):1979. PubMed ID: 33785741
    [Abstract] [Full Text] [Related]

  • 19. SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate cancer.
    Li H, Wang L, Li Z, Geng X, Li M, Tang Q, Wu C, Lu Z.
    Lab Invest; 2020 Apr 30; 100(4):570-582. PubMed ID: 31772313
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.